Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc-regulated GTPase metalloprotein activator 1F (ZNG1F) is a member of the COG0523 protein family, functioning as a zinc chaperone that directly transfers zinc to selected metalloproteins, notably methionine aminopeptidase 1 (METAP1) in vertebrates[1][2][7]. ZNG1F catalyzes the transfer of zinc from a high-affinity binding site in its GTPase domain to the active site of METAP1 through a GTP hydrolysis-dependent mechanism, thus enabling the protease to cleave initiator methionine residues from nascent polypeptides during or after translation[2]. The protein is predicted to reside in the cytoplasm and nucleus, and is essential for intracellular zinc homeostasis, especially under conditions of zinc deprivation[1][2]. Mutations in ZNG1 homologs disrupt mitochondrial function and organismal development in animal models, but ZNG1F is not currently described as a validated therapeutic target or associated with any approved drugs[2]. The molecule's alternative names include CBWD6, CBWD7, and COBW domain-containing protein 6[1][7]. Notes on correctness and ambiguity: - There is no established evidence in the literature or curated therapeutic target databases that ZNG1F is a validated drug target, receptor, or transporter (thus, is_target is false)[1][2][7]. - The extensive alias list includes symbols that may reference related/overlapping family members; the most scientifically accurate human gene symbol is ZNG1F, HGNC:31978[1]. - ZNG1F is a specific zinc chaperone, not a receptor or enzyme with classic druggable activity. - No interacting drugs, biomarker roles, or known safety/therapeutic issues are currently described. - If a user expected a receptor or established therapeutic target, this is not the case—thus, is_incorrect = true for a classic drug target context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc-regulated GTPase metalloprotein activator 1F (ZNG1F).